Sidley Represents Hanmi Pharm and Green Cross Biopharma in Licensing Agreement With BioMarin

Sidley represented GC Biopharma Corp. and Hanmi Pharm Co., Ltd. in an exclusive licensing agreement with BioMarin Pharmaceutical Inc. for LA-GLA (HM15421/GC1134A), a jointly developed next-generation therapy for Fabry disease. The agreement is valued at up to US$475 million, including a US$70 million upfront payment and up to US$405 million in milestone payments, and additional royalties upon commercialization. Under the agreement, BioMarin will lead global development and commercialization of LA-GLA, while GC Biopharma and Hanmi Pharm will oversee regulatory approval and commercialization in South Korea. The therapy, currently in a global Phase 1/2 clinical trial, is designed to reduce treatment burden for patients with Fabry disease.

The Sidley team was led by Josh Hofheimer (Technology and Life Sciences Transactions) and included Lauren Grau, Sabrina Glavota, and Jonathan Trang (Technology and Life Sciences Transactions), Michael P. Alcan and Sophie Arkusinski (Tax); Idan Netser (Emerging Companies and Venture Capital); Lauren Kitces (Privacy and Cybersecurity); Tomoki Ishiara (M&A); Trevor L. Wear (Healthcare); Taylor Andelman (Healthcare); and Kelly Cho (Food, Drug and Medical Device).